Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. However, not all innovations are equal and nor do they follow a constant upward trend.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

Pharmaceutical Technology

FEBRUARY 23, 2023

DNA binding site prediction, peptide structure optimisation, and AI-assisted genome analysis are some of the accelerating innovation areas, where adoption has been steadily increasing. However, not all innovations are equal nor do they follow a constant upward trend.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Pharmaceutical Technology

MARCH 9, 2023

Innovation S-curve for the pharmaceutical industry Transgenic murine models is a key innovation area in pharmaceutical s Transgenic murine models refer to mice that have been genetically altered for the purposes of understanding the in vivo functions of genes.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

Drug Discovery World

JANUARY 23, 2023

Our team has been focused on engineering mRNA so that it’s only used to express cargo protein in certain cells regardless of where the molecule ends up in the body. JB : Strand was founded in 2018, and our programmable mRNA technology has broad applicability across a variety of diseases.

RNA 98

RNA Genome Genomics Engineer 98

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. CRISPR allows researchers to target and edit specific genes in order to better understand the genome, human diseases and the effects of specific mutations. What are organoids? .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

The Pharma Data

JANUARY 12, 2021

KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies. and retain royalties on all ex-U.S. sales for that product.

Development 52

Development Research In-Vivo Genome 52

XTalks

DECEMBER 20, 2023

AI and Machine Learning: Transforming Research Artificial intelligence (AI) and machine learning (ML) are revolutionizing research approaches in the life sciences. Below are some of the key trends that will be shaping the future of the life sciences in 2024 and beyond.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Improving the quality of the DNA is as important as improving the speed of synthesis.” .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

FEBRUARY 6, 2023

The company is co-founded by former team leaders and multi-disciplinary tool builders from 10x Genomics. We isolate antibodies from single human B cells using single cell genomics and assess, engineer, and advance these antibodies with other technologies. This has consequences for safety and efficacy.

Antibody 52

Antibody Immune Response Genome Genomics 52

Drug Discovery World

SEPTEMBER 14, 2023

Business updates Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year quarter, reflecting an operational decline of $14.7 Vaccines were up 9.1%

Drugs 59

Drugs Vaccination Vaccine Medicine 59

Drug Discovery World

JANUARY 23, 2023

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. Pioneering work in the mid-2000s, led by the Yamanaka group at Kyoto University, further advanced the field of PSCs.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Delveinsight

FEBRUARY 25, 2021

Instead of snipping the genome, base editing lets for edits of individual letters in a genetic sequence. Electroporation is used for ex vivo delivery of therapies to blood and immune cells. Beam announced that it paid USD 120 million upfront to acquire Guide Therapeutics in an all-stock agreement.

DNA 52

DNA In-Vivo Genetics Medicine 52

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.

Gene Expression 112

Gene Expression Development RNA Drugs 112

The Pharma Data

JANUARY 4, 2021

Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. Barber is an associate professor of biology and director of the Office of Student Research. “We believe Prof. About PD-1 Check-point inhibition.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . Last year saw the sector surge, with levels of investment hitting an all-time high at $22.7

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

OCTOBER 17, 2022

Data lakes served this same purpose, but while the idea was good, the results of search engines were often disappointing. For example, GEO, the gene expression omnibus database, has been collecting gene expression and functional genomics datasets and making them available to the public for more than 20 years.

Marketing 52

Marketing Scientist Gene Expression Drugs 52

The Pharma Data

DECEMBER 10, 2020

ImmunityBio has engineered the vector to overcome this problem and has shown that its second-generation adenovirus vector can safely and effectively deliver its cargo even in patients with pre-existing adenovirus immunity. This blocking of viral replication was observed in both the lung and nasal passages.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52